Daiichi Sankyo Co Ltd

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO® (pexidartinib) at the Connective Tissue Oncology Society (#CTOS2024) 2024 Annual Meeting. TURALIO is the first and only oral systemic therapy approved in the U.S. for adult patients with tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare.

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET Company Participants Hiroyuki Okuzawa - Representative Director, President & Chief Operating Officer Ken Takeshita - Global Head of Research & Development Koji Ogawa - Head of Global Corporate Planning & Management, Chief Financial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Kazuki Hashiguchi - Daiwa Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Kasumi Haruta - UBS Hiroshi Wada - SMBC Koichi Mamegano - BofA Global Research Miki Sogi - Bernstein Michael Nedelcovych - TD Cowen Tony Ren - Macquarie Hiroyuki Okuzawa This is Okuzawa. Thank you for taking time out of your busy schedule to attend Daiichi Sankyo's Financial Results Presentation today.

Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positive breast cancer. Enhertu has multiple approvals, including tissue-agnostic for high HER2 expression, while datopotamab deruxtecan shows promise in non-squamous NSCLC. Recent findings support ifinatamab deruxtecan's potential to outperform topotecan in second-line treatment, signaling a significant advancement for Daiichi Sankyo's oncology pipeline.

Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance

Merck

Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.

Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases.

ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO.

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrill.

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corporate Planning & Management, CFO Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Kazuki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley MUFG Kasumi Haruta - UBS Michael Nedelcovych - TD Cowen Miki Sogi - Sanford Bernstein Unidentified Company Representative Thank you very much for joining Daiichi Sankyo's Financial Results Presentation ought to be a very busy schedule today. I'm going to explain FY2024 first quarter of financial results.

Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript

ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's strong commitment to addressing treatment needs of people living with cancer in the European region. Thomais Konstantopoulou has been appointed Country Manager, Daiichi Sankyo Greece Single Member S.A. “We are very happy to open yet another new affiliate in Europe to bring our innovative medicines t.

Daiichi Sankyo Opens New Affiliate for Oncology in Greece

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys' fees and costs plus interest awarded by the arbitrator of the party's dispute. Arbitration History and the Award In August of 2022, an arbitrator issued a decision in a dispute between Daiichi Sankyo and Seagen denying all claims made by Seagen and confirming that Daii.

Arbitration Dispute Between Daiichi Sankyo and Seagen Ends

Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising results in HER2+ breast cancer, while Dato-DXd offers billions in potential revenue from lung and breast cancer. Daiichi Sankyo has an attractive pipeline, including compounds in trials for small-cell lung cancer, ovarian cancer, EGFR-mutated NSCLC, as well as an emerging second-gen ADC technology portfolio.

Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuzawa - Representative Director, President and COO Ken Takeshita - Head of Global R&D Koji Ogawa - Head of Global Corporate Planning & Management, CFO Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Kasumi Haruta - UBS Securities Koichi Mamegano - BOA Securities Miki Sogi - Sanford Bernstein Kentaro Asakura [Foreign Language] Thank you for waiting. We would like to open Fiscal Year 2023 Financial Results Presentation.

Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript

AstraZeneca

The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript

Seagen

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.'s U.S. patent 10,808,039 (the '039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR). “We are pleased that the U.S. PTO invalidated all challenged claims of the '039 patent,” said Naoto Tsukaguchi, Corporate.

U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen

Esperion Therapeutics

Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration.  Daiichi Sankyo Europe GmbH, the company's European arm, agreed to pay Esperion $100 million ahead of an expected Type II(a) variation approval by the European Medicines Agency for a pair of drugs, NILEMDO and NUSTENDI.

Esperion resolves legal dispute with Daiichi Sankyo ahead of likely European drug approval

Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

PARIS--(BUSINESS WIRE)--Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader's RNA-targeted drug discovery program. Based on magnetic force spectroscopy, MAGNA is a unique technology that enables high-throughput analysis of dynamic biomolecular interactions in real time with single-molecule resolution. In the case of RNA, these insights reveal how small molecules and proteins bind to three.

Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH.

Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH

A Japanese health ministry panel on Monday recommended approval for an updated version of Daiichi Sankyo's COVID-19 vaccine, the Kyodo news agency said.

Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine.

Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine

MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced the appointment of its new Managing Director Masahiro Kato and new Head of the European Speciality Business Unit, Oliver Appelhans. Masahiro succeeds Dr. Jan Van Ruymbeke, who successfully led the European organisation over the last 11 years and who will retire by end of March 2024. During his tenure the European organisatio.

Change in Leadership at Daiichi Sankyo Europe

Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown promising early-stage clinical data in various cancers. While there are risks associated with the efficacy and toxicity of these drugs, the collaboration with Merck provides financial security and further potential for success.

Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion

Drugmaker Merck (MRK) agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of the Japanese company's candidate cancer drugs.

Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion

Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candidates.

News for Daiichi Sankyo Co Ltd Stock (DSNKY)